Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study - Wikidata - awgldk - TriplyDB

Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study

Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study

http://www.wikidata.org/entity/Q28482219

about

Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib Understanding, recognizing, and managing toxicities of targeted anticancer therapies.Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity.Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.Genotypes Affecting the Pharmacokinetics of Anticancer Drugs.Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age?Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.The adverse effects of sorafenib in patients with advanced cancers.Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib.PharmGKB summary: sorafenib pathways.Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib.Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma.In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study.Association of Single Nucleotide Polymorphisms in STAT3 with Hand-Foot Skin Reactions in Patients with Metastatic Renal Cell Carcinoma Treated with Multiple Tyrosine Kinase Inhibitors: A Retrospective Analysis in Japanese Patients.Sorafenib and sunitinib: A dermatologist's perspective.Pseudocirrhosis caused by regorafenib in an advanced rectal cancer patient with multiple liver metastases.Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma.Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.Fractionation of daily dose increases the predicted risk of severe sorafenib-induced hand-foot syndrome (HFS).Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma.Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma.How 'Optimal' are Optimal Sampling Times for Tyrosine Kinase Inhibitors in Cancer? Practical Considerations.Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study.

P2860

Q26765210-5C7950D2-A9BC-44A7-8D17-E54CEEF15259 Q33408049-F6B72AE5-0BA5-4D97-BD1E-5E83FDC15E9A Q33411001-AF46BF64-955D-4C50-84C6-CB2C03069B13 Q33418378-2507A575-0834-4E59-B584-8251C56336CB Q33434697-CE60D63E-D3A1-47C9-871E-13A2349DF705 Q35856250-983C9EE2-4524-44A9-9E58-51DE88588E33 Q37685527-C704E540-3D7F-4BB1-B6D7-C0737B924D87 Q38162294-7C72CCDC-93C2-4FFC-9786-543CB75F0BAC Q38190857-05DAC9B1-77FD-42F9-BA80-CC45032150A6 Q38201503-2DFE9B6C-20B1-4DF8-8153-D409917B33C9 Q38286308-8B062DFD-02F6-4279-913C-4EB3258BDB88 Q38391227-CA64F134-FEC4-421E-8C81-1493FB6408FF Q38864682-094B8F53-9DCA-47A0-AB8A-9F7C781487D3 Q39429946-9C266902-5BD9-4972-BBD6-2FE4DB627E26 Q39473582-5CD796E3-B068-48C6-8061-ACB1C8821A2E Q40698804-19D7ED54-455C-4D4F-AE4A-AE2824EC3489 Q41092089-BD7A58C1-1167-443D-94EE-894D64F9D384 Q41458660-13C7D276-45D8-47D7-8309-92D1CBB28BC4 Q41983823-C472B080-6A2B-422E-815D-0CDEE1AA7F13 Q42329758-C258CA3E-2C89-4F56-A5DF-28F214435761 Q43406043-602E8C0C-65DF-458B-BD5A-3CEB72AE39F9 Q43515674-EA554117-4DCE-4C2E-8DC4-0E2207E63253 Q44252023-DBBA9EF7-33E3-434C-8334-713A4553E9A6 Q44921787-940E83DF-93DF-403E-A54F-9E2B68621F56 Q47969048-19438F00-7F66-451E-AEAE-74B8E5E8A8E3 Q48306032-AC097F38-A607-4897-A3FB-D0645DDA62AD Q48826707-A4D3D049-1A10-492E-A401-0853F2905167 Q51099990-78561742-5E09-44DA-B0B7-2B840B42EE02

P2860

Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study

http://www.wikidata.org/entity/Q28482219

description

2012 nî lūn-bûn

@nan

2012 թուականին հրատարակուած գիտական յօդուած

@hyw

2012 թվականին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

name

Early sorafenib-induced toxici ...... id tumors: a preliminary study

@ast

Early sorafenib-induced toxici ...... id tumors: a preliminary study

@en

Early sorafenib-induced toxici ...... id tumors: a preliminary study

@nl

type

label

Early sorafenib-induced toxici ...... id tumors: a preliminary study

@ast

Early sorafenib-induced toxici ...... id tumors: a preliminary study

@en

Early sorafenib-induced toxici ...... id tumors: a preliminary study

@nl

prefLabel

Early sorafenib-induced toxici ...... id tumors: a preliminary study

@ast

Early sorafenib-induced toxici ...... id tumors: a preliminary study

@en

Early sorafenib-induced toxici ...... id tumors: a preliminary study

@nl

P1433

Q28482219-7E2E3770-30E8-490D-9070-2FAFA5F5D388

P1476

Q28482219-A4CBC478-D876-4E77-8774-F3A665E1B006

P2093

Q28482219-380BB862-F690-4EBA-A1CC-D271FA8B78BC

Q28482219-38F5B570-92F3-4F2D-AC33-2238C06515C7

Q28482219-40793D53-4C67-423F-BF1A-BF1ACBE87776

Q28482219-681CDFC7-0BCD-41C3-A5B8-55C55F36EF80

Q28482219-8ABAA743-0706-41F2-8C50-16959D701C47

Q28482219-97254C48-3372-431D-8872-A00D225025BB

Q28482219-99C74237-E090-49CA-B6BC-CE8FA1162F4D

Q28482219-BB9A2AA3-2FA2-416C-A786-02E2E8ABEA81

Q28482219-E56D3F88-D4D8-4256-97FB-70D937CC055E

Q28482219-FA451FC6-4E98-4694-9D38-9FFC7AC066BD

P2860

Q28482219-03A66D39-AA0F-47DB-B9B0-EB02F48E94EC

Q28482219-0A65B1F3-5727-488F-94A8-13836F6EE942

Q28482219-1BC3D632-657B-468C-AAEC-9DB05D6AF85D

Q28482219-1BFE02F4-1A49-403D-8913-E17C2C3BD95A

Q28482219-28570364-BCC9-4D6C-9B84-2CCEDD787930

Q28482219-28AB892F-1E22-4EE9-A7B8-76A77F2FFA96

Q28482219-3DA86129-EC55-4949-AC13-1D8B8B9BEEFB

Q28482219-52881680-AAB9-4045-AD9B-FE3636CE0F00

Q28482219-555CEA77-AB17-4EC3-A00A-913F400DAED0

Q28482219-555D38B5-E552-4CC4-A0CC-FC4D497604E2

P304

Q28482219-BCA56945-6C8A-40D2-9431-ADDD332CFCF7

P31

Q28482219-732796ED-418B-4DC1-8030-BCC7B7D7449B

P356

Q28482219-0A5409C3-E4E9-48D6-B55C-795D4C7591A5

P407

Q28482219-ECFB516E-51E2-4F5D-A378-477955F40AF1

P433

Q28482219-165BBBC5-353E-450E-8520-592BE7EB2A25

P478

Q28482219-8A7CFFC7-78C2-4256-8B63-30C88C18625E

P50

Q28482219-1FE8F67D-B519-4020-B8D0-ABEC78888905

Q28482219-75CA2D6A-2715-4CD6-A5EC-E1BE972E4038

Q28482219-8DC4FAE6-29F4-4960-9E15-2E4BD05D0EC4

Q28482219-A1F942AF-75DA-4BE1-952C-F470DA95A903

Q28482219-CFC5FF0B-018B-42CC-9EF8-A378B20E9E22

P577

Q28482219-BEF0591B-72BA-475F-AFB1-6F2E197D1D49

P5875

Q28482219-997E464C-2F54-4A26-80AE-405C1B520B92

P698

Q28482219-400E6EAB-F19F-455E-B1FA-E234FC5DCDAC

P932

Q28482219-ED4F9825-9333-43AE-8F3A-2A96B5D548F7

P356

JOURNAL.PONE.0042875

P1433

P1476

Early sorafenib-induced toxici ...... id tumors: a preliminary study

@en

P2093

Alain Dauphin

http://www.w3.org/2001/XMLSchema#string

Audrey Thomas-Schoemann

http://www.w3.org/2001/XMLSchema#string

Benoit Blanchet

http://www.w3.org/2001/XMLSchema#string

Fabrice Taieb

http://www.w3.org/2001/XMLSchema#string

François Goldwasser

http://www.w3.org/2001/XMLSchema#string

Jean Louis Golmard

http://www.w3.org/2001/XMLSchema#string

Jean-Philippe Durand

http://www.w3.org/2001/XMLSchema#string

Michel Tod

http://www.w3.org/2001/XMLSchema#string

Pascaline Boudou-Rouquette

http://www.w3.org/2001/XMLSchema#string

Romain Coriat

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain.

Clinical pharmacokinetics of tyrosine kinase inhibitors.

Population pharmacokinetic analysis of sorafenib in patients with solid tumours.

Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib.

Intestinal tract injury by drugs: Importance of metabolite delivery by yellow bile road.

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.

Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib.

Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.

P304

e42875

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0042875

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Marie-Anne Loriot

Pascaline Boudou-Rouquette

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230716379

http://www.w3.org/2001/XMLSchema#string

P698

22912756

http://www.w3.org/2001/XMLSchema#string

P932

3418266

http://www.w3.org/2001/XMLSchema#string